The review builds its central hypothesis—mutant LRRK2 sensitizes microglia toward a pro-inflammatory phenotype—on three evidence pillars: (1) LRRK2 is expressed and induced in microglia and peripheral immune cells, and LPS-induced inflammation raises LRRK2 protein and activity in mouse SNpc/striatum ; (2) LRRK2 knockdown or mutation alters inflammatory output—knockdown attenuates LPS-induced TNF-α, IL-1β, IL-6, iNOS and NF-κB activity, while the R1441G knockin microglia show basal upregulation of activation markers and increased pro-inflammatory cytokine secretion after LPS ; (3) LRRK2 kinase activity is needed for microglial migration, cytoskeletal remodeling, and phagocytosis, with the inhibitor IN-1 protecting axons from pathological microglial phagocytosis .
The authors are appropriately candid that much of the vesicle-trafficking role in microglia is speculation: the strongest Rab/SNARE data come from neurons, and they explicitly label the extension to microglia as a hypothesis. This epistemic honesty is a strength, but it means Figure 1's unified model rests on inference, not direct measurement.
Subsequent studies broadly confirmed the inflammatory-competence axis but exposed its limits. Quantitative MSD assays show endogenous G2019S raises pT73-Rab10 ~2-fold in mouse astrocytes and ~1.5-fold in human PBMCs, and that inflammatory stimulation (IFN-γ, lysosomal stress) elevates LRRK2 activity in iPSC-derived microglia—supporting the immune-cell angle . But a critical blindspot emerged: in LRRK2-knockout rat striatum, pT73-Rab10 falls only ~30%, and in some brain contexts phosphorylation persists, implying additional kinases or regulatory mechanisms . Furthermore, LRRK2 kinase inhibition triggers proteasome-dependent LRRK2 degradation, meaning chronic inhibitor approaches risk confounding kinase inhibition with protein loss—a pharmacological confound not anticipated by the 2014 review .
A well-organized, honest, and broadly correct 2014 synthesis whose core inference—that LRRK2 mutations bias microglia toward inflammation—has aged reasonably well, but whose mechanistic scaffolding is heavily built on overexpression data, single-genotype evidence, and rodent models later shown to diverge from human inflammatory regulation. It is a good hypothesis-generating review, not a definitive mechanistic account.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.